| Authors: |
Untch M; Interdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin, Germany. Electronic address: michael.untch@helios-gesundheit.de., Pérol D; Centre Léon Bérard, Lyon, France., Mayer EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cortes J; International Breast Cancer Center (IBCC), Grupo Quiron, Madrid & Barcelona, Spain., Nusch A; Practice for Hematology and Internal Oncology, Velbert, Germany., Cameron D; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK., Barrios C; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Delea T; Policy Analysis Inc. (PAI), Boston, MA, USA., Danyliv A; Novartis Pharma AG, Basel, Switzerland., Mishra N; Novartis Healthcare Pvt Ltd, Hyderabad, India., Gupta R; Novartis Healthcare Pvt Ltd, Hyderabad, India., Pathak P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Fasching PA; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. |
